Rakesh Jhunjhunwala raises stake in this infra stock; do you own it?
The ace investor has increased stake by 0.72% in the infrastructure company through his wife Rekha Jhunjhunwala's portfolio.
rakesh jhunjhunwala
April 2022
March 2022
February 2022
December 2021
Analysts see 20% upside in this Rakesh Jhunjhunwala-backed stock; do you own it?
Ace investor Rakesh Jhunjhunwala and his wife Rekha Jhunjhunwala together own a 17.51% stake in this health insurance company.
This Rakesh Jhunjhunwala-backed stock jumps 5%; analysts see more upside
Analysts at Motilal Oswal have initiated a ‘buy’ coverage on the stock with a target price of ₹750 per share amid earnings optimism and improvement in the overall health insurance industry.
This Rakesh Jhunjhunwala stock gains 25% in one week; hits upper circuit 4th time
This stock has generated 550% returns in 11 months, rising from its 52-week low of ₹16.75 in April 2021, to ₹110 in intraday today.
This stock hit 5% upper circuit as Rajesh Jhunjhunwala buys stake
This multibagger stock has risen 100% since the beginning of the calendar year 2022 and 170% over the past one year.
This Rakesh Jhunjhunwala-backed realty stock zoomed 400% in 6 months
This multibagger stock has hit upper circuit for 8 sessions amid fund raising plans.
DB Realty ropes in Rakesh Jhunjhunwala after Godrej calls off deal
The Mumbai-based realty firm will issue 10 million warrants each to Rekha Jhunjhunwala and RARE Enterprises, which is owned by Rakesh Jhunjhunwala.
Metro Brands to Star Health: How Jhunjhunwala-backed IPOs did since listing
Footwear retailer Metro Brands is the second Rakesh Jhunjhunwala-backed company after Star Health and Allied Insurance that failed to impress investors on listing day.
This Rakesh Jhunjhunwala-backed multibagger stock rallied 180% in one year
This Rakesh Jhunjhunwala-backed realty stock surged as much as 178% over the past one year, as compared to 22% growth in the benchmark index BSE Sensex.
Even Rakesh Jhunjhunwala investments go awry; here's one
Rakesh Jhunjhunwala-backed Star Health and Allied Insurance failed to impress investors as it delivered a negative return of 8% since its debut on December 10.
